Akathisia;Akathisie

Fortschritte der Neurologie Psychiatrie

Volumn 65, Issue 9, 1997, Pages 396-406

  Brune M ^a   Braunig P ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; BEHAVIOR; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IMPULSIVENESS; MOTOR DYSFUNCTION; RESTLESSNESS;

EID: 0030810535     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996344     Document Type: Article

References (80)

1. Adler, L. A., B. Angrist, S. Reiter, J. Rotrosen: Neuroleptic-induced akathisia: A review. Psychopharmacology 97 (1989) 1-11
2. Adler, L. A., B. Angrist, N. Weinreb: Studies of the time course and efficacy of b-blockers in neuroleptic - induced akathisia and the akathisia of idiopathic Parkinson's disease. Psychopharmacol. Bull. 27 (1991) 107-111
3. Ayd, F. J. Jr.: A survey of drug-induced extrapyramidal reactions. J. Am. Med. Assoc. 175 (1961) 1054-1060
4. Ayd, F. J. Jr.: Early-onset neuroleptic-induced extrapyramidal reactions: a second survey, 1961-1981. In: Coyle, J. T., S. J. Enna (eds.): Neuroleptics: neurochemical, behavioral, and clinical perspection. Raven Press, New York 1983
5. Barnes, T. R. E., W. M. Braude: Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry 42 (1985) 874-878
6. Barnes, T. R. E.: The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatric Developments 4 (1987) 301-319
7. Barnes, T. R. E.: A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
8. Barnes, T. R. E., S. M. Halstead, P. W. A. Little: Relationship between iron status and chronic akathisia in an in-patient population with chronic schizophrenia. Br. J. Psychiatry 161 (1992) 791-796
9. Barnes, T. R. E., J. M. Kane: Assessment of movement disorder in psychosis. In: Barnes, T. R. E. (ed.): The assessment of psychosis - A practical handbook. London 1994
10. Beasley, C M., G. Tollefson, P. Tran, W. Satterlee, T. Sanger, S. Hamilton: Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14 (1996) 111-123
11. Bing, R.: Über einige bemerkenswerte Begleiterscheinungen der "extrapyramidalen Rigidität" (Akathisia, Mikrographie, Kinesia paradoxa). Schweiz. Med. Wochenschr. 4 (1923) 167-171
12. Bing, R.: Textbook of Nervous Diseases. CV Mosby, St. Louis (1939) p. 169
13. Blaisdell, G. D.: Akathisia: A comprehensive review and treatment summary: Pharmacopsychiatry 27 (1994) 139-146
14. Blom, S., K. A. Ekbom: Comparison between akathisia developing on treatment with phenothiazine derivates and the restlesslegs syndrome. Acta Med. Scand. 170 (1961) 689-694
15. Braude, W. M., T. R. E. Barnes: Late-onset akathisia - an indicant of covert dyskinesia: Two case reports. Am. J. Psychiatry 140 (1983) 611-612
16. Brown, K. W., T. White: Pseudoakathisia and negative symptoms in schizophrenic subjects. Acta Psychiatr. Scand. 84 (1991) 107 -109
17. Brüne, M., P. Bräunig: Kompendium der Akathisie. Thieme, Stuttgart, New York 1997
18. Casey, D. E.: Extrapyramidal syndromes. Epidemiology, Pathophysiology and the diagnostic dilemma. CNS Drugs 5 (Suppl.) (1996) 1-12
19. Caughey, J. E.: Akathisia (restless-legs). NZ. Med. J. 100 (1987) 121
20. Chengappa, K. N. R., M. D. Shelton, R. W. Baker, N. R. Schooler, J. Baird, J. Delaney: The prevalence of akathisia in patients receiving stable doses of clozapine, J. Clin. Psychiatry 55 (1994) 142 -145
21. Claghorn, J., G. Honigfeld, F. S. Abuzzahab: The risks and benefits of clozapine vs. chlorpromazine. J. Clin. Psychopharmacol. 7 (1987) 377-384
22. Cohen, B. M., P. E. Keck, A. Satlin, J. O. Cole: Prevalence and severity of akathisia in patients on clozapine. Biol. Psychiatry 29 (1991) 1215-1219
23. Comella, C. L., C. G. Goetz: Akathisia in Parkinson's disease. Mov. Disord. 9 (1994) 545-549
24. Dieterle, D. M., F. Müller-Spahn, M. Ackenheil: Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten. Fortschr. Neurol. Psychiat. 59 (1991) 18-22
25. Drake, R. E., J. Ehrlich: Suicide attempts associated with akathisia. Am. J. Psychiatry 142 (1985) 499-501
26. Dufresne, R. L., R. L Wagner: Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: Further evidence for the existence of tardive akathisia. J. Clin. Psychiatry 49 (1988) 435-438
27. Dunn, C.J., A. Fitton: Sertindole. CNS Drugs 5 (1996) 224-230
28. Ekbom, K. A.: Restless-legs syndrome. Neurology 10 (1960) 868-873
29. Fleischhacker, W. W., C. H. Miller, K. J. Bergmann: Die neurolepti-kainduzierte Akathisie. Nervenarzt 60 (1989) 719-723
30. Fleischhacker, W. W., U. J. Bergmann, R. Perovich, L. U. Pestreich, M. Borenstein, J. A. Lieberman, J. M. Kane: The Hillside Akathisia Scale: a new rating instrument for neuroleptic induced akathisia. Psychopharmacol. Bull. 25 (1989) 222-226
31. Fleischhacker, W. W., S. D. Roth, J. M. Kane: The pharmacologic treatment of neuroleptic - induced akathisia. J. Clin. Psychopharmacol. 10 (1990) 12-21
32. Fournier, M., Rawak: Parästhesien und Unruhe der Extremitäten. Nervenarzt 25 (1954) 123-124
33. Freyhan, F. A.: Therapeutic implications of differential effects of new phenothiazine compounds. Am. J. Psychiatry 115 (1959) 577-585
34. Friis, T., T. R. Christensen, J. Gerlach: Sodium valproate and biperiden in neuroleptic-induced akathisia, Parkinsonism and hyperkinesia: Acta Psychiatr. Scand. 67 (1983) 178-187
35. Gibb, W. R. G., A. J. Lees: The clinical phenomenon of akathisia. J. Neurol. Neurosurg. Psychiatry 49 (1986) 861-866
36. Gold, R., R. H. Lenox: Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. J. Clin. Psychiatry 56 (1995) 476-483
37. Grohmann, R., E. Rüther, L. G. Schmidt (Hrsg.): Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie. Springer, Berlin, Heidelberg, New York 1994
38. Halstead, S. M., T. R. E. Barnes, J. C Speller: Akathisia: Prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br. J. Psychiatry 164 (1994) 177-183
39. Haskovec, L: L'Akathisie. Rev. Neurol. 9 (1901) 1107-1109
40. Haskovec, L: Akathisia. Arch. Bohemes. Med. Clin. 3 (1902) 193-200
41. Haskovec, L: Weitere Bemerkungen über die Akathisie. Wien. Med. Wschr. 54 (1904) 528-529
42. Hodge, J. R.: Akathisia: The syndrome of motor restlessness. Am. J. Psychiatry 116 (1959) 337-338
43. Kahn, E. M., M. R. Munetz, M. A. Davies, S. C. Schulz: Akathisia: Clinical phenomenology and relationship to tardive dyskinesia. Compr. Psychiatry 33 (1992) 233-236
44. Keckich, W. A.: Violence as manifestation of akathisia. JAMA 24 (1978) 2185
45. Kurz, M., M. Hummer, H. Oberbauer, W. W. Fleischhacker: Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 118 (1995) 52-56
46. Lang, A. E., K. Johnson: Akathisia in idiopathic Parkinson's disease. Neurology 37 (1987) 477-481
47. Lipinski, J. F., J. I. Hudson, S. L. Cunningham, H. G. Aizley. P. E. Keck, G. Mallya, R. B. Aranow, S. E. Lukas: Polysomnographic characteristics of neuroleptic-induced akathisia. Clin. Neuropharmacol. 14 (1991) 413-419
48. Marsden, C. D., P. Jenner: The pathophysiology of extrapyramidal side - effects of neuroleptic drugs. Psychol. Med. 10 (1980) 55 -72
49. McCreadie, R. G., R. Thara, S. Kamath, R. Padmavathy, S. Latha, N. Mathrubootham, M. S. Menon: Abnormal movements in never-medicated Indian patients with schizophrenia. Br. J. Psychiatry 168 (1996) 221-226
50. Miller, C. H., W. W. Fleischhacker, H. Ehrmann, J. M. Kane: Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol. Bull. 26 (1990) 373-376
51. Miller, C. H., D. S. G. Umbricht, J. A. Lieberman, F. Mohr, W. W. Fleischhacker: The prevalence and severity of acute extrapyramidal side effects in patients treated with clozapine, risperidone or conventional antipsychotics. American Psychiatric Association, Annual Meeting, May 4-9, New York 1996
52. Munetz, M. R., C. L. Cornes: Akathisia, pseudoakathisia and tardive dyskinesia: Clinical examples. Compr. Psychiatry 23 (1982) 345-352
53. Munetz, M. R., C. L. Cornes: Distinguishing akathisia and tardive dyskinesia: A review of the literature. J. Clin. Psychopharmacol. 3 (1983) 343-350
54. National Institute of Mental Health: Psychopharmacology survey center collaborative study group. Phenothiazine treatment in acute schizophrenia. Arch. Gen. Psychiatry 10 (1964) 161 -246
55. Newcomer, J. W., L. S. Miller, W. O. Faustman, M. W. Wetzel, G. P. Vogler, J. G. Csernansky: Correlation between akathisia and residual psychopathology: A by-product of neuroleptic-induced dysphoria. Br. J. Psychiatry 164 (1994) 834-838
56. Rapoport, A., D. Stein, A. Grinshpoon, A. Elizur: Akathisia and pseudoakathisia: Clinical observations and accelerometric recordings. J. Clin. Psychiatry 55 (1994) 473-477
57. Raskin, D. E.: Akathisia: A side effect to be remembered. Am. J. Psychiatry 129 (1972) 345-347
58. Rosebush, P. L, M. F. Mazurek: Neurological side effects of risperidone. American Psychiatric Association, Annual Meeting, May 4-9, New York 1996
59. Sabaawi, M., T. F. Holmes, M. R. Fragala: Drug-induced akathisia: Subjective experience and objective findings. Mil. Med. 159 (1994) 286-291
60. Sachdev, P., C. Loneragan: The present status of akathisia. J. Nerv. Ment. Dis. 179 (1991) 381-391
61. Sachdev, P., J. Kruk: Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch. Gen. Psychiatry 51 (1994) 963-974
62. Sachdev, P.: Research diagnostic criteria for drug-induced akathisia: Conceptualization, rationale and proposal. Psychopharmacology 114 (1994a) 181-186
63. Sachdev, P.: A rating scale for acute drug-induced akathisia: development, reliability, and validity. Biol. Psychiatry 35 (1994b) 263-271
64. Sachdev, P.: The identification and management of drug-induced akathisia. CNS Drugs 4 (1995a) 28-46
65. Sachdev, P.: The development of the concept of akathisia: a historical overview. Schizophr. Res. 16 (1995b) 33-45
66. Sachdev, P.: The epidemiology of drug-induced akathisia: part I: acute akathisia. Schizophr. Bull. 21 (1995c) 431-449
67. Sachdev, P.: The epidemiology of drug-induced akathisia: part II: chronic, tardive, and withdrawal akathisias. Schizophr. Bull. 21 (1995d) 451-461
68. Sachdev, P.: Akathisia and restless legs syndrome. Cambridge University Press, 1995e
69. Schulte, J. L: Homicide and suicide associated with akathisia and haloperidol. Am. J. Forensic. Psychiatry 6 (1985) 3-7
70. Seidel, M.: Phänomenologie und Therapie der neuroleptika-induzierten Akathisie - eine Literaturübersicht. Fortschr. Neurol. Psychiat. 57 (1989) 489-494
71. Sicard, J. P.: Akathisie et tasikinesie. Presse Med. 31 (1923) 265-266
72. Sigwald, J., A. Grossiord, P. Duriel, G. Dumont: Le traitement de la maladie de Parkinson et des manifestations extrapyramidales par le diethylaminoethyl n - thiophenylamine (2987 RP): resultats d'une anee d'application. Rev. Neurol. 79 (1947) 683-687
73. Steck, H.: Le syndrome extrapyramidal et d'encephalique au cours des traitements au largactil et au serpasil. Ann. Med. Psychol. 112 (1954) 737-743
74. Street, J. S., M. A. Dellva, R. N. Tamura, T. Sanger, G. D. Tollefson: Comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia. American Psychiatric Association, Annual Meeting, May 4-9, New York 1996
75. Van Putten, T.: Why do schizophrenic patients refuse to take their drugs? Arch. Gen. Psychiatry 31 (1974) 67-72
76. Van Putten, T.: The many faces of akathisia. Compr. Psychiatry 16 (1975) 43-47
77. Van Putten, T., P. R. A. May, S. R. Marder: Akathisia with haloperidol and thiothixene. Arch. Gen. Psychiatry 41 (1984) 1036-1039
78. Weiden, P. J., J. Mann, G. Haas, M. Mattson, A. Frances: Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am. J. Psychiatry 144 (1987) 1148-1153
79. Wetzel, H., A. Szegedi, C. Hain, J. Wiesner, S. Schlegel, O. Benkert: Seroquel (ICI 204636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119 (1995) 231-238
80. Zimbroff, D. L., R. J. Mack, J. Zborowski, D. D. Morris, T. B. Sebree, B. A. Wallin: The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. American Psychiatric Association, Annual Meeting, May 4-9, New York 1996